Related Experiment Video
Updated: May 27, 2025

Strategies for Assessing Autistic-Like Behaviors in Mice
Published on: September 20, 2024
Phenotypic rescue via mTOR inhibition in neuron-specific Pten knockout mice reveals AKT and mTORC1-site specific
Angelica D'Amore1, Maria Sundberg1, Rui Lin1
1Department of Neurology, FM Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Abstract:
Phosphatase and Tensin Homolog (PTEN) is a dual-specific protein and lipid phosphatase that regulates AKT and downstream signaling of the mechanistic target of rapamycin (mTOR). PTEN functions as a tumor suppressor gene whose mutations result in PTEN Hamartoma Tumor Syndrome (PHTS) characterized by increased cancer risk and neurodevelopmental comorbidity. Here, we generated a novel neuron-specific Pten knock-out mouse model (Syn-Cre/Pten HOM) to test the ability of pharmacologic mTOR inhibition to rescue Pten mutation-associated disease phenotypes in vivo and in vitro. We found that treatment with the mTOR inhibitor, everolimus, increased the survival of Syn-Cre/Pten HOM mice while some neurologic phenotypes persisted. Transcriptomic analyses revealed that in contrast to mice harboring a neuron-specific deletion of the Tuberous Sclerosis Complex 2 gene (Syn-Cre/Tsc2 KO), genes that are under AKT regulation were significantly increased in the Syn-Cre/Pten HOM mice. In addition, genes associated with synapse, extracellular matrix, and myelination were broadly increased in Syn-Cre/Pten HOM mouse neocortex. These findings were confirmed by immunostaining of cortical sections in vivo, which revealed excessive immunoreactivity of myelin basic protein and perineuronal nets (PNN), the specialized extracellular matrix surrounding fast-spiking parvalbumin (PV) interneurons. We also detected increased expression of Synapsin I/PSD95 positive synapses and network hyperactivity phenotypes in Syn-Cre/Pten HOM mice neurons compared to wild-type (WT) neurons in vitro. Strikingly, everolimus treatment rescued the number of synapses and network hyperactivity in the Syn-Cre/Pten HOM mice cortical neuron cultures. Taken together, our results revealed in vivo and in vitro molecular and neuronal network mechanisms underlying neurological phenotypes of PHTS. Notably, pharmacologic mTOR inhibition by everolimus led to successful downstream signaling rescue, including mTOR complex 1 (mTORC1) site-specific suppression of S6 phosphorylation, correlating with phenotypic rescue found in our novel neuron-specific Syn-Cre/Pten HOM mice.
Insights
Pharmacologic mTOR inhibition with everolimus partially rescued neurological deficits in a novel mouse model of PTEN Hamartoma Tumor Syndrome (PHTS). The treatment improved survival and rescued synaptic and network hyperactivity, revealing therapeutic potential for PHTS-associated neurodevelopmental disorders.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Phosphatase and Tensin Homolog (PTEN) is a tumor suppressor regulating AKT/mTOR signaling.
- PTEN mutations cause PTEN Hamartoma Tumor Syndrome (PHTS), linked to cancer and neurodevelopmental issues.
- Understanding PTEN's role in neurological disease is crucial for therapeutic development.
Purpose of the Study:
- To generate and characterize a neuron-specific Pten knock-out mouse model (Syn-Cre/Pten HOM).
- To investigate the efficacy of mTOR inhibition (everolimus) in rescuing Pten mutation-associated neurological phenotypes.
- To elucidate the molecular and neuronal network mechanisms underlying PHTS neurological comorbidities.
Main Methods:
- Generated novel neuron-specific Pten knock-out mice (Syn-Cre/Pten HOM).
- Treated mice and cultured neurons with the mTOR inhibitor everolimus.
- Performed transcriptomic analyses, immunostaining, and in vitro electrophysiology.
- Assessed survival rates and neurological phenotypes.
Main Results:
- Everolimus treatment increased Syn-Cre/Pten HOM mouse survival but did not fully resolve all neurological phenotypes.
- Transcriptomic analysis revealed increased AKT-regulated genes and genes related to synapses, extracellular matrix, and myelination in Syn-Cre/Pten HOM mice.
- In vitro studies showed increased synapses and network hyperactivity in Syn-Cre/Pten HOM neurons, which were rescued by everolimus.
- Immunostaining confirmed increased myelin basic protein and perineuronal nets (PNNs).
Conclusions:
- The study established a novel mouse model for PHTS neurological phenotypes.
- Pharmacologic mTOR inhibition demonstrated therapeutic potential by rescuing specific molecular and neuronal network abnormalities.
- Findings provide insights into the molecular mechanisms of PHTS neurodevelopmental comorbidities and highlight mTOR as a therapeutic target.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
08:12Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins
Published on: January 8, 2018
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
In-vitro Mutagenesis
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...